Effect of Ranolazine After Deferral of Percutaneous Coronary Intervention by Fractional Flow Reserve (IMWELL3)

Trial Profile

Effect of Ranolazine After Deferral of Percutaneous Coronary Intervention by Fractional Flow Reserve (IMWELL3)

Discontinued
Phase of Trial: Phase II

Latest Information Update: 31 Mar 2017

At a glance

  • Drugs Ranolazine (Primary)
  • Indications Angina pectoris
  • Focus Therapeutic Use
  • Acronyms IMWELL3
  • Most Recent Events

    • 27 Mar 2017 Status changed from recruiting to discontinued.
    • 17 Aug 2015 Status changed from not yet recruiting to recruiting, as reported by ClinicalTrials.gov.
    • 07 Oct 2014 Planned initiation date changed from 1 Jun 2014 to 1 Dec 2014 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top